+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
5-Alpha Reductase Deficiency Market by Type, End Users, Age Group, Diagnosis Technique, Treatment - Global Forecast 2025-2030- Product Image
5-Alpha Reductase Deficiency Market by Type, End Users, Age Group, Diagnosis Technique, Treatment - Global Forecast 2025-2030- Product Image
Sale

5-Alpha Reductase Deficiency Market by Type, End Users, Age Group, Diagnosis Technique, Treatment - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6014980
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The 5-Alpha Reductase Deficiency Market grew from USD 1.17 billion in 2023 to USD 1.28 billion in 2024. It is expected to continue growing at a CAGR of 9.82%, reaching USD 2.26 billion by 2030.

5-Alpha Reductase Deficiency (5-ARD) is a rare genetic condition characterized by the insufficient production of dihydrotestosterone, affecting male sexual development. The market for related diagnostic and therapeutic applications is driven by the increasing awareness and enhanced diagnostic technologies. The necessity of addressing 5-ARD lies in its significant impact on patients, necessitating accurate diagnosis and tailored treatment solutions, with applications spanning genetic testing, hormone therapy, and surgical interventions. The end-use scope primarily involves healthcare providers, diagnostic labs, and specialized medical research facilities. Key growth factors include advancements in genetic screening technologies, a growing understanding of rare genetic disorders, and the increasing focus on personalized medicine. These factors are complemented by strategic collaborations between research institutes and pharmaceutical companies aimed at innovation in treatment options. Emerging opportunities encompass the evolving field of genomic medicine and the integration of AI in predictive diagnostics, optimizing patient outcomes and creating new avenues for market expansion. However, the market faces limitations such as the rarity of the condition leading to limited research funding, high-cost barriers for genetic testing, and the complexity of treatment protocols. Additionally, the lack of awareness and insufficient medical professional training can hinder accurate diagnosis. Addressing these challenges involves increasing global awareness and training programs, reducing diagnostic costs through innovative technologies, and enhancing funding support for rare disease research. The best areas of innovation include developing cost-effective genetic screening tools, advancing targeted hormonal therapies, and leveraging AI for early and precise diagnosis. The market exhibits moderate growth potential, heavily reliant on technological advancements and the ability to bridge knowledge gaps in rare genetic conditions. For business growth, stakeholders should focus on collaboration between technology providers and healthcare institutions to enhance treatment protocols, driving both market penetration and improved patient care outcomes.

Understanding Market Dynamics in the 5-Alpha Reductase Deficiency Market

The 5-Alpha Reductase Deficiency Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing prevalence of 5-alpha reductase deficiency raising demand for advanced diagnostic and therapeutic interventions
    • Increasing awareness and better understanding of genetic disorders enhancing early diagnosis and treatment
    • Rising healthcare expenditure and government initiatives promoting research and development in rare genetic conditions
    • Innovative treatment options and biotechnological advancements driving growth in 5-alpha reductase deficiency treatments
  • Market Restraints
    • Limited patient awareness and diagnosis challenges hinder market growth for 5-alpha reductase deficiency
  • Market Opportunities
    • Leveraging digital health technologies to create a robust patient support network for those with 5-alpha reductase deficiency
    • Collaborating with international pharmaceutical companies to fast-track clinical trials for new treatments addressing 5-alpha reductase deficiency
    • Establishing partnerships with healthcare providers for integrated care models to enhance quality of life for 5-alpha reductase deficiency patients
  • Market Challenges
    • Stringent regulatory requirements and approval processes, slowing down the introduction of new treatments in the 5-alpha reductase deficiency market

Exploring Porter’s Five Forces for the 5-Alpha Reductase Deficiency Market

Porter’s Five Forces framework further strengthens the insights of the 5-Alpha Reductase Deficiency Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the 5-Alpha Reductase Deficiency Market

External macro-environmental factors deeply influence the performance of the 5-Alpha Reductase Deficiency Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the 5-Alpha Reductase Deficiency Market

The 5-Alpha Reductase Deficiency Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the 5-Alpha Reductase Deficiency Market

The 5-Alpha Reductase Deficiency Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the 5-Alpha Reductase Deficiency Market

The 5-Alpha Reductase Deficiency Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the 5-Alpha Reductase Deficiency Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the 5-Alpha Reductase Deficiency Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Primary 5-Alpha Reductase Deficiency
      • Type 1
      • Type 2
    • Secondary 5-Alpha Reductase Deficiency
      • Acquired
      • Congenital
  • End Users
    • Clinics
    • Hospitals
    • Research Institutes
    • Specialty Treatment Centers
  • Age Group
    • Adolescents
    • Adults
    • Pediatric
  • Diagnosis Technique
    • Genetic Testing
      • Chromosomal Analysis
      • DNA Analysis
    • Hormone Testing
      • Dihydrotestosterone (DHT) Levels
      • Serum Testosterone Levels
    • Radiological Imaging
      • MRI
      • Ultrasound
  • Treatment
    • Hormone Replacement Therapy
      • Androgens
      • Estrogens
    • Monitoring And Follow-Up
    • Psychological Support
    • Surgical Interventions
      • Genital Reconstruction
      • Gonadectomy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of 5-alpha reductase deficiency raising demand for advanced diagnostic and therapeutic interventions
5.1.1.2. Increasing awareness and better understanding of genetic disorders enhancing early diagnosis and treatment
5.1.1.3. Rising healthcare expenditure and government initiatives promoting research and development in rare genetic conditions
5.1.1.4. Innovative treatment options and biotechnological advancements driving growth in 5-alpha reductase deficiency treatments
5.1.2. Restraints
5.1.2.1. Limited patient awareness and diagnosis challenges hinder market growth for 5-alpha reductase deficiency
5.1.3. Opportunities
5.1.3.1. Leveraging digital health technologies to create a robust patient support network for those with 5-alpha reductase deficiency
5.1.3.2. Collaborating with international pharmaceutical companies to fast-track clinical trials for new treatments addressing 5-alpha reductase deficiency
5.1.3.3. Establishing partnerships with healthcare providers for integrated care models to enhance quality of life for 5-alpha reductase deficiency patients
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements and approval processes, slowing down the introduction of new treatments in the 5-alpha reductase deficiency market
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. 5-Alpha Reductase Deficiency Market, by Type
6.1. Introduction
6.2. Primary 5-Alpha Reductase Deficiency
6.2.1. Type 1
6.2.2. Type 2
6.3. Secondary 5-Alpha Reductase Deficiency
6.3.1. Acquired
6.3.2. Congenital
7. 5-Alpha Reductase Deficiency Market, by End Users
7.1. Introduction
7.2. Clinics
7.3. Hospitals
7.4. Research Institutes
7.5. Specialty Treatment Centers
8. 5-Alpha Reductase Deficiency Market, by Age Group
8.1. Introduction
8.2. Adolescents
8.3. Adults
8.4. Pediatric
9. 5-Alpha Reductase Deficiency Market, by Diagnosis Technique
9.1. Introduction
9.2. Genetic Testing
9.2.1. Chromosomal Analysis
9.2.2. DNA Analysis
9.3. Hormone Testing
9.3.1. Dihydrotestosterone (DHT) Levels
9.3.2. Serum Testosterone Levels
9.4. Radiological Imaging
9.4.1. MRI
9.4.2. Ultrasound
10. 5-Alpha Reductase Deficiency Market, by Treatment
10.1. Introduction
10.2. Hormone Replacement Therapy
10.2.1. Androgens
10.2.2. Estrogens
10.3. Monitoring And Follow-Up
10.4. Psychological Support
10.5. Surgical Interventions
10.5.1. Genital Reconstruction
10.5.2. Gonadectomy
11. Americas 5-Alpha Reductase Deficiency Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific 5-Alpha Reductase Deficiency Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa 5-Alpha Reductase Deficiency Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET RESEARCH PROCESS
FIGURE 2. 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. 5-ALPHA REDUCTASE DEFICIENCY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. 5-ALPHA REDUCTASE DEFICIENCY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. 5-ALPHA REDUCTASE DEFICIENCY MARKET DYNAMICS
TABLE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ACQUIRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONGENITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHROMOSOMAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIHYDROTESTOSTERONE (DHT) LEVELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SERUM TESTOSTERONE LEVELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ANDROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY MONITORING AND FOLLOW-UP, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PSYCHOLOGICAL SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENITAL RECONSTRUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GONADECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 86. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 88. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 89. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 90. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 92. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 93. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 94. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 95. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 97. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 105. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 106. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 107. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 148. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 150. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 151. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 152. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 154. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 155. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 156. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 157. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 159. CHINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 160. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 162. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 163. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 164. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 166. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 167. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 168. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 169. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 170. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 171. INDIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 184. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 186. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 187. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 188. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 190. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 191. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 192. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 193. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 195. JAPAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 244. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 245. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 246. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 256. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 258. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 259. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 260. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 262. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 263. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 264. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 265. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 266. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 267. THAILAND 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE TESTING, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 293. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 294. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIMARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 295. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SECONDARY 5-ALPHA REDUCTASE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 296. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 297. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 298. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2030 (USD MILLION)
TABLE 29

Companies Mentioned

The leading players in the 5-Alpha Reductase Deficiency Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.26 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

5-Alpha Reductase Deficiency Global Market Report 2024 - Product Image

5-Alpha Reductase Deficiency Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
5-Alpha Reductase Inhibitor - Pipeline Insight, 2024 - Product Image

5-Alpha Reductase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Steroid Biochemistry. Methods in Enzymology Volume 689 - Product Image

Steroid Biochemistry. Methods in Enzymology Volume 689

  • Book
Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026 - Product Image

Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026

  • Report
  • 95 Pages
  • Global
From
Ribonucleotide reductase inhibitors - Pipeline Insight, 2024 - Product Image

Ribonucleotide reductase inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.